Trial Profile
Biomarker Study of Patients With Metastatic Clear Cell Renal Carcinoma (ccRCC) Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- Acronyms SuAx
- 02 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 24 Jul 2018 New trial record